Save
Email
Print
ShareScienceDaily (Nov. 29, 2011) — In research at SRI International, scientists evaluating new drug targets against tuberculosis (TB) recently validated the preclinical effectiveness of a target that could rapidly eliminate infections and potentially shorten treatment time. The new drug target is a protein called DNA gyrase B, found in bacteria that cause TB infections.
DNA gyrase is an enzyme consisting of two subunits: gyrase A and gyrase B. Although gyrase A is often the target of antibiotics, such as ciprofloxacin, there currently is no antibiotic on the market that targets gyrase B. In laboratory experiments, SRI researchers found that by targeting gyrase B, TB bacteria are killed whether they are replicating or dormant. Further studies will be conducted toward the development of a TB drug against gyrase B.
"One of the greatest needs in infectious disease treatment is a drug that allows a shorter length of treatment," said Peter Madrid, Ph.D., program director in the Center for Infectious Disease and Biodefense Research, SRI Biosciences Division. "Though our program is still in the preclinical phase of research, with a number of years of required testing ahead, our goal is to develop a drug that will improve the treatment process for TB patients."
TB patients currently undergo treatment for six months and take a combination of at least four different drugs. There are often challenges to treatment effectiveness because of the long treatment time, including low patient treatment compliance and high rates of drug resistance. Tuberculosis that is resistant to multiple drugs takes even longer to treat, usually 18 to 24 months.
Research results are presented in the November 2011 Journal of Antimicrobial Chemotherapy in a paper titled "Evaluation of Gyrase B as a Drug Target in Mycobacterium tuberculosis."
The project described was supported by Award Numbers R56AI090817 and U01AI082070 from the National Institute of Allergy And Infectious Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health.
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by SRI International.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Journal Reference:
- S. Chopra, K. Matsuyama, T. Tran, J. P. Malerich, B. Wan, S. G. Franzblau, S. Lun, H. Guo, M. C. Maiga, W. R. Bishai, P. B. Madrid. Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy, 2011; DOI: 10.1093/jac/dkr449
Note: If no author is given, the source is cited instead.
Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.
more 
